DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/c4fe32/addiction_control) has announced the addition of GlobalData's new report "Addiction Control - Drug Pipeline Analysis and Market Forecasts to 2015" to their offering.

Addiction Control - Drug Pipeline Analysis and Market Forecasts to 2015

"Addiction Control - Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global addiction control market. The report identifies the key trends shaping and driving the global addiction control market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global addiction control sector.

Addiction Control Therapeutics Market is Forecasts to Show Significant Growth until 2015

The global addiction control therapeutics market was valued at $2.7 billion in 2008 and will be driven by the increasing addictive population. This market is expected to grow to $5.3 billion with a CAGR of 10% by year 2015. As the market has fewer treatment options, patients and physicians are not left with much choice, which translates into high prescription rates of existing branded products and other generic products, which keeps market growing. In addition, the successful launch of some of the vaccines such as NicVAX, TA-NIC and TA-CD, currently in Phase II will significantly stimulate the market growth. However, the lack of any novel therapeutic with curative properties and the patent expiry of the current market therapies such as Suboxone/Subutex and Campral will pose a barrier for market growth.

Strong Pipeline Candidates Raise Hope of an Addiction Control Treatment Paradigm Shift

The authors have found that products for addiction control in the developmental pipeline are strong with over 240 molecules in various phases of clinical development. There are over 20 first-in-class molecules in different stages of clinical development. These molecules have distinct advantages over the current marketed players in term of better efficacy and safety profiles. These molecules are primarily first-in-class molecules, which demonstrates the robustness of the addiction control pipeline as the market is demanding new entrants with novel treatments and re-formulation designs to offer long-term abstinence and high safety profiles. There are 41 molecules in Phase III making up to 17% of overall pipeline. The Phase II clinical stage has highest contribution with over 146 molecules making up to 59% of the addiction control pipeline. NicVAX, TA-NIC, TA-CD, Revex, CYT002-NicQb and other promising molecules with features such as better efficacy, better tolerability and safety profiles are the most keenly watched products in addiction control pipeline portfolio.

Current Marketed Products are Unsuccessful in Meeting Patients' Expectations

The current competition is weak and the marketed products are unsuccessful in meeting the patients' demands leaving behind a larger segment of unmet need. Because the products currently in market do not serve the unmet need of curing the disease, the market continues to present opportunities for stronger pipeline candidates. The current drugs are mainly offering brief withdrawal from addictive substances. Additionally, the current market is mainly driven by a smaller number of branded drugs and generics. This underexploited market holds significant market potential for any new entrants with disease modifying capability. Designing disease modifying drugs rather than drugs for brief withdrawal is one of key challenges for this market and could provide a significant opportunity for any company.

Bulk of Pipeline Portfolio is Maintained by Major Market Players

The bulk of the addiction control portfolio is maintained by leading companies in the market. Among the companies participating in the addiction control market, Eli Lilly, GlaxoSmithKlein (GSK), Alkermes Pharmaceuticals, Nicobrand (Watson Pharmaceuticals) and Titan Pharmaceuticals are the key players. However, governmental bodies and universities, such as the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA) are also active, with a large number of molecules under clinical study for addiction control.

GSK has one Phase II and Preclinical and two Phase I molecules, Eli Lilly has two molecules in each of Phase I and II, Alkermes pharmaceuticals has two Phase II and one Phase III molecules, Nicobrand (Watson Pharmaceuticals) has two molecules in regulatory filing. Titan pharmaceutical has one Phase III molecule and one molecule in Preclinical stage.

Scope

The scope of the report includes:

• Annualized global addiction control market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
• Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
• Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include nicotinic acetylcholine receptors receptor targetters, dopamine-serotonin receptor targetters, GABA receptors targetters, adrenergic receptors targetters, opioid receptor targetters and cannabinoid receptor targetters.
• Analysis of the current and future market competition in the global addiction control market. Key market players covered are Eli Lilly and Company, GSK, Alkermes pharmaceuticals, Nicobrand (Watson Pharmaceuticals) and Titan pharmaceuticals.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with addiction control.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global addiction control market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global addiction control market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Key Topics Covered:

1 Table of contents

2 Addiction Control Market: Market Characterization

3 Addiction Control Market: Competitive Assessment

4 Addiction Control Market: Pipeline Assessment

5 Addiction Cotrol Market: Implications for Future Market Competition

6 Addiction Control Market: Future Players in Addiction Control Market

7 Addiction Control Market: Appendix

Companies Mentioned:

• GlaxoSmithKline
• Eli Lilly
• Alkermes
• Titan Pharmaceuticals
• Nicobrand (Watson Pharmaceuticals)

For more information visit http://www.researchandmarkets.com/research/c4fe32/addiction_control

Research and Markets
Laura Wood, Senior Manager
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Source: Research and Markets